Modality
Nanobody
MOA
JAK1i
Target
Nectin-4
Pathway
Wnt
Alzheimer's
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
~Jul 2020
→ ~Oct 2021
Phase 3
~Jan 2022
→ ~Apr 2023
NDA/BLA
Jul 2023
→ May 2031
NDA/BLACurrent
NCT08234599
511 pts·Alzheimer's
2023-07→2031-05·Terminated
511 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-035.1y awayPh3 Readout· Alzheimer's
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2031-05-03 · 5.1y away
Alzheimer's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08234599 | NDA/BLA | Alzheimer's | Terminated | 511 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα |